Allergan 10-Q2020 Q1 Quarterly report

Filed: 7 May 20, 8:03am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: alpha, API, argument, Asia, AstraZeneca, autoimmune, behavior, biodegradable, broadest, built, buyer, Cadila, certainty, chain, composition, confirm, confirming, contamination, continent, Coolsculpting, CoolTone, Cream, cystic, declare, deliver, detailing, discontinuation, discontinued, distancing, Durysta, electronic, enrolling, environment, enzyme, Esthetique, evolve, exocrine, experienced, Gedeon, genericization, glaucoma, globe, half, home, hypertension, inability, indirectly, inhibitor, innovation, insufficiency, intracameral, intraocular, IOP, Ireland, Lab, Lazeo, LIBOR, lifetime, local, logistical, losing, medial, minute, mitigate, Nestle, OAG, ocular, OHT, outbreak, Pacific, pancreatic, pandemic, patient, pressure, rebate, recession, recovery, relationship, remotely, reply, Richter, satisfaction, Science, shelter, spent, spread, strain, susceptible, suspended, temporarily, Ubrelvy, unemployment, Viokace, Vital

Removed: absence, acceleration, acid, add, adjunctive, advancement, affirming, Akorn, Akron, Apotex, appellate, applied, Argentum, asserting, authorize, automatically, back, binding, BioMed, Biomedical, Body, bound, buy, calculate, calculated, capitalized, capitalizing, Center, centralized, certiorari, chosen, clarify, cloud, collateralization, collateralized, commonly, computing, concurrently, Contouring, contractually, conversion, correct, corrected, Corrupt, cumulative, delaying, Delzicol, denial, denying, Depressive, dermatology, determining, Deva, disgorgement, Disorder, dozen, Easement, enablement, enacted, enforceable, Envy, equaled, equipment, equitable, error, established, estate, Europe, exemption, exercised, expedient, explicitly, Famy, fiscal, fleet, fourth, Framework, gamma, GILTI, ground, Harbor, HD, higher, hosted, immunity, implementation, implicit, implicitly, improper, incorrectly, India, Influenced, InnoPharma, institute, instrument, intent, invalidity, inventorship, issuing, joinder, LA, land, lease, leasing, Legacy, legally, lessee, lessor, Lidoderm, LifeCell, limit, Low, mandatorily, mandatory, MDD, modified, modify, noncancelable, notification, offsetting, older, opening, option, orphan, ownership, package, pattern, Pennsylvania, pension, permission, pertaining, Pharmacal, pivotal, plant, Plastic, postretirement, practical, preferred, prepaid, preventing, privately, pronouncement, prospectively, purpose, qualify, Racketeer, rapastinel, rating, reaching, real, receptor, reclassification, reclassify, recognition, redeemed, refinancing, released, remove, renew, renewal, rental, Replacement, represented, requiring, residual, restitution, resurfacing, retinoic, retired, retrospective, retrospectively, revaluation, reversing, RORyt, ROU, SA, scaling, shortened, skin, Slayback, software, sovereign, standalone, statutory, stranded, substantive, substitute, Subtopic, suit, supplier, Surgery, suspension, Targeted, Taxed, TCJA, terminate, Therapy, threshold, topline, treble, tribal, TWi, Ubrogepant, unrelated, updated, USD, vendor, VI, Vitae, withdraw, withdrew, writ

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Allergan similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. of Section 1350, as Adopted by

Section 906 of the Sarbanes-Oxley Act of 2002

The undersigned officer of Allergan plc (the “Company”), hereby certifies, to such officer’s knowledge, that:

(i) the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Allergan plc.

Date: May 7, 2020

By:		/s/ BRENTON L. SAUNDERS
		Brenton L. Saunders
		Chairman, President and Chief Executive Officer
		(Principal Executive Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. of Section 1350, as Adopted by

Section 906 of the Sarbanes-Oxley Act of 2002

The undersigned officer of Warner Chilcott Limited (the “Company”), hereby certifies, to such officer’s knowledge, that:

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Warner Chilcott Limited.

Date: May 7, 2020

By:		/s/ BRENTON L. SAUNDERS
		Brenton L. Saunders
		Chairman, President and Chief Executive Officer
		(Principal Executive Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.